Click Here to return To Results

 

A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Dissease NEJM 327:1253-1259, 13061992., Davis,K.L.,et al, 1992 See this aricle in Pubmed Article Abstract At the end of the six-week trial,the patients receiving tacrine had a mean adjusted cognitive-subscale score of 30.3(Alzheimer's Disease Assessment Scale)as compared with 32.7 in patients receiving placebo.This represents a smaller decline(by 2.4 points)in cognitive performance in the tacrine group(P<0.001).There were no differences between the groups in their global-rating scores.The tacrine group had a significantly smaller decline in the activities of daily living.The results of the Mini-Mental State Examination favored tacrine,but the differences were small and not statistically significant(a score of 16.0 with tacrine vs.15.3 with placebo;P=-.08).Gastrointestinal symptoms,elevation of aminotransferase levels,and headache were the most frequent side effects;all could be reversed by reducing the dose or discontinuing treatment.In this short- term study in patients with Alzheimer's disease who were selected for apparent responsiveness to tacrine,treatment with tacrine resulted in a statistically significant reduction in the decline of cognitive function, although this reduction was not large enough to be detected by the study physicians'global assessments of the patients.

Related Tags

(click to filter results - removes previous filter) Alzheimer's disease Alzheimer's disease,treatment of anticholinesterase dementia dementia,treatment of tetrahydroaminoacridine treatment of neurologic disorder

Click Here to return To Results